BLOG / 🇺🇸 United States / distress insolvency · · daily

US Corporate Distress Financial Stress SEC Filings — September 01, 2026

USA Corporate Distress & Bankruptcy

By Gunpowder Editorial ·

8 high priority 8 total filings analysed

Executive Summary

The digest reveals a sharp and concentrated wave of distress across eight US-listed companies, centred overwhelmingly on Nasdaq listing deficiencies and acute solvency risks.

The dominant theme is a cascade of late-filing violations, with four separate companies (XTI Aerospace, Borealis Foods, CID Holdco, Heritage Distilling) receiving delinquency notices for missing their Q2 2026 10-Q deadlines, pointing to systemic accounting or disclosure issues. The most severe event is BioXcel Therapeutics entering Chapter 11 bankruptcy, a binary outcome that underscores the ultimate crystallization of distress. Insider activity is notably absent across all filings, weakening management's credibility as a signalling tool. Period-over-period comparisons were sparse in these event-driven disclosures, but the sheer density of going-concern warnings (XTI Aerospace) and compound listing failures (authID, CID Holdco) signals that a subset of micro-cap names is facing a liquidity and governance crunch. The critical market implication is that the delisting risk is not isolated; each new deficiency creates a compounding risk that can accelerate the timeline to bankruptcy or forced M&A, as seen in BioXcel's case.

Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →

Filing types in this digest: 8-K

Tracking the trend? Catch up on the prior US Corporate Distress Financial Stress SEC Filings digest from August 24, 2026.

Investment Signals (8)

  • BioXcel Therapeutics ↓ (BEARISH)
    ▲

    Filed Chapter 11, common stock likely worthless. No insider buying signal. Litigation and administrative costs will consume remaining value.

  • XTI Aerospace ↓ (BEARISH)
    ▲

    Expects to disclose 'substantial doubt' as a going concern in its delinquent Q2 2026 10-Q. Former CEO resigned on 17 Aug, triggering a still-incomplete internal review. Compliance deadline just 60 days away (Oct 26).

  • Borealis Foods ↓ (BEARISH)
    ▲

    Nasdaq deficiency for late Q2 2026 filing linked to an unresolved accounting review of a Conversion Agreement requiring shareholder approval. A positive spin: no immediate suspension, and it has a 180-day cure path. But the accounting uncertainty could delay resolution.

  • CID Holdco ↓ (BEARISH)
    ▲

    Third Nasdaq staff determination for delisting—accumulated bases include failure to file 10-Q, minimum MVLS ($50M), and minimum MVPHS ($15M). Only 7 days to request an extended stay. The multi-failure pattern suggests a terminal loss of compliance.

  • authID ↓ (BEARISH)
    ▲

    Failed minimum bid price ($1.00) for 30 consecutive days. Already non-compliant with stockholders' equity requirement (Rule 5550(b)(1)), which blocks a second 180-day cure period. Delisting is almost certain unless a reverse split is urgently approved and lifts the stock.

  • Heritage Distilling (IPST) (BEARISH)
    ▲

    Late 10-Q filing; intends to file in September but offers no guarantee. A single delinquency is not yet terminal, but it joins a growing peer group of companies struggling with timely SEC reporting.

  • Barinthus Biotherapeutics ↓
    ▲

    Delisting and deregistration are confirmed (effective 9 Sep) following a court-sanctioned Scheme of Arrangement for a merger. This is a structural event, not a distress signal per se, but it removes liquidity for shareholders. [NEUTRAL/BEARISH]

  • U.S. GoldMining ↓
    ▲

    Audit committee independence failure after a board resignation. Cure period until August 2027—ample time, but the market may penalize governance gaps. [NEUTRAL/BEARISH]

Risk Flags (8)

  • BioXcel Therapeutics/Bankruptcy↓ [HIGH RISK]
    ▼

    Common stock recovery expected to be zero. Filing triggers a delisting process. The company must operate under strict DIP facility restrictions, and any failure to obtain court approval for motions accelerates liquidation.

  • XTI Aerospace/Going Concern↓ [HIGH RISK]
    ▼

    The company explicitly warns its upcoming 10-Q will express substantial doubt. This follows a former CEO resignation and an unresolved internal review. If the Nasdaq compliance plan is rejected, the company could face simultaneous delisting and bankruptcy.

  • authID/Compound Delisting Risk↓ [HIGH RISK]
    ▼

    Two simultaneous Nasdaq non-compliances (bid price and stockholders' equity). The equity deficiency (Rule 5550(b)(1)) is a hard barrier to a second cure period. A reverse stock split would address bid price but not equity—placing the company in a 'no-win' compliance trap.

  • CID Holdco/Multiple Delisting Bases↓ [HIGH RISK]
    ▼

    Three separate grounds for delisting—missing the 10-Q, sub-$50M MVLS, and sub-$15M MVPHS. The company's seven-day window to request a further stay is about to expire (3 Sep). Even if a hearing is granted, the odds of reversing all three bases are extremely low.

  • Borealis Foods/Accounting Uncertainty↓ [MODERATE RISK]
    ▼

    Filing delay stems from a review of a Conversion Agreement that requires shareholder approval. If the accounting treatment is complex and the disclosure is poor, Nasdaq may reject the compliance plan, or shareholders could reject the related equity issuance.

  • Heritage Distilling/Compliance Non-Assurance↓ [MODERATE RISK]
    ▼

    Company 'intends' to file in September but provides no guarantee. A rejection of its compliance plan by Nasdaq could trigger an appeal process that consumes time and management bandwidth.

  • U.S. GoldMining/Governance Gap↓ [LOW-MODERATE RISK]
    ▼

    A single audit committee vacancy. While the cure period is long, the resignation 'not due to a disagreement' is standard language. If the company fails to find an independent director before the next AGM, it could face delisting.

  • All Companies/Absence of Insider Activity [IMPLICIT RISK]
    ▼

    Across all eight filings, there is zero insider buying recorded. In distress situations, insider buying is a powerful signal of management's belief in a turnaround. Its absence, combined with former CEO departures (XTI) and board exits (U.S. GoldMining), suggests a lack of conviction among those closest to the business.

Opportunities (6)

  • BioXcel Therapeutics/Chapter 11 Sale↓ (OPPORTUNITY)
    ◆

    For distressed-debt investors, the court-supervised sale transaction may offer an opportunity to buy claims at a discount. The 8-K mentions a 'DIP Facility'—if the sale clears bankruptcy, secured creditors could recover, while equity is zero.

  • authID/Reverse Split Catalyst↓ (SPECULATIVE OPPORTUNITY)
    ◆

    The company may consider a reverse stock split to regain bid-price compliance. If the equity deficiency is cured in parallel (e.g., via a capital raise), the stock could surge from distressed levels. However, the risk is high.

  • Borealis Foods/Resolution Catalyst↓ (SPECULATIVE OPPORTUNITY)
    ◆

    If Borealis resolves the Conversion Agreement accounting review and files its 10-Q before the Oct 26 deadline, the Nasdaq notice will be removed, eliminating a key overhang. The stock could re-rate if the underlying business fundamentals are sound.

  • XTI Aerospace/Compliance Plan Acceptance↓ (SPECULATIVE OPPORTUNITY)
    ◆

    Nasdaq may accept XTI's compliance plan, granting an extension until Feb 2027. If the company files its 10-Q with a going-concern note but a credible financing plan, the delisting risk could be deferred, opening a trading window.

  • Heritage Distilling/Quick Filing Catalyst↓ (SPECULATIVE OPPORTUNITY)
    ◆

    The company expects to file its Q2 10-Q in September 2026. If it meets this timeline, the Nasdaq deficiency is fully cured without an extension, proving better than expected internal controls.

  • U.S. GoldMining/Arbitrage Opportunity↓ (OPPORTUNITY)
    ◆

    The market may overreact to the audit committee vacancy. Given the long cure period (until Aug 2027), the company has ample time to find an independent director. A quick appointment could cause the stock to gap higher.

Sector Themes (4)

  • Late-Filing Epidemic [SYSTEMIC RISK]
    ◆

    4 out of 8 filings (50%) involve missed 10-Q deadlines, all within a one-week period (Aug 26-27). This clustering suggests sector-agnostic accounting/control failures, possibly tied to complex transactions (conversion agreements, internal reviews) that strain small-cap finance functions.

  • Nasdaq as Gatekeeper [POLICY RISK]
    ◆

    Nearly all filings (7/8) are directly triggered by Nasdaq deficiency notices. The exchange is increasingly enforcing listing standards, including independence (U.S. GoldMining), equity requirements (authID), and timely filings (XTI, Borealis, CID, Heritage). This creates a binary outcome environment where non-compliance quickly escalates to delisting.

  • Going-Concern Acceleration [DOWNSIDE RISK]
    ◆

    XTI Aerospace is the only filing explicitly warning of 'substantial doubt,' but BioXcel's Chapter 11 is the real-world outcome. This pattern suggests that going-concern language in Nasdaq filings is a leading indicator for bankruptcy, not a benign disclosure.

  • Zero Insider Confidence (BEARISH CONSENSUS)
    ◆

    Across 8 filings, there is not a single insider purchase or sale disclosed. In a typical distress sample, some insiders would attempt to signal confidence or monetize. The complete absence here implies that management teams lack conviction (or are precluded by blackout periods) in a turnaround.

Watch List (8)

  • BioXcel Therapeutics/Chapter 11 Sale↓ (CRITICAL)
    👁

    Monitor court approvals for the DIP Facility and any stalking-horse bid. If the sale fails to attract a buyer, the company may convert to Chapter 7 liquidation. Timeline: ongoing.

  • authID/Stockholders' Equity Compliance↓ (HIGH)
    👁

    The company must resolve its equity deficiency (Rule 5550(b)(1)) or face near-certain delisting by Feb 23, 2027. Watch for a capital raise or reverse split announcement. Date: cure deadline Q1 2027.

  • CID Holdco/Hearing Request↓ (HIGH)
    👁

    The company has until Sept 3 to request an extended stay. If no request is made, delisting is immediate. If requested, the hearing panel's decision will determine the stock's fate. Date: Sept 3+15 days.

  • XTI Aerospace/Compliance Plan Submission↓ (HIGH)
    👁

    Deadline Oct 26 to submit a plan to Nasdaq. Watch for any pre-announcement of the 10-Q or the internal review outcome. Date: Oct 26, 2026.

  • Borealis Foods/10-Q Filing↓ (MODERATE)
    👁

    The company must resolve its accounting review for the Conversion Agreement and file the Q2 10-Q. Watch for 8-K disclosing shareholder approval or accounting conclusions. Date: before Oct 26, 2026.

  • Heritage Distilling/10-Q Filing↓ (MODERATE)
    👁

    Company expects to file in September 2026. Any delay beyond that month will reset the compliance timeline. Watch for the actual filing date. Date: September 2026.

  • U.S. GoldMining/Independent Director Appointment↓ (LOW)
    👁

    The board's search for an independent director will remove the Nasdaq deficiency. A quick appointment (within weeks) would be a positive governance signal. Date: before next AGM (likely mid-2027).

  • Barinthus Biotherapeutics/Delisting Effective Date↓ (MODERATE)
    👁

    Trading halt scheduled before Sep 9 open. After that, the ADS will be deregistered, eliminating any secondary market. Date: Sep 9, 2026.

Filing Analyses (8)
BioXcel Therapeutics, Inc. 8-K negative materiality 10/10

01-09-2026

BioXcel Therapeutics, Inc. (BTAI) filed an 8-K on September 1, 2026, disclosing that it has commenced Chapter 11 bankruptcy proceedings (the 'Cases') and is pursuing a sale transaction (the 'Transaction') under court supervision. The filing highlights significant risks including potential delisting, inability to continue as a going concern, and substantial uncertainty for common stockholders, who may receive little or no recovery. The company faces heightened administrative and legal costs, potential litigation, and risks of failing to obtain court approvals or complete the transaction.

  • · The company is operating under Chapter 11 protection and requires court approval for motions filed in the Cases.
  • · The company must comply with restrictions under its financing arrangements, including the DIP Facility.
  • · The Chapter 11 process may result in common stockholders receiving no recovery.
  • · The company faces risks of termination of the asset purchase agreement and potential adverse reactions from suppliers, vendors, partners, employees, and regulatory authorities.
  • · The filing includes forward-looking statements and disclaims any obligation to update them.
XTI Aerospace, Inc. 8-K negative materiality 9/10

01-09-2026

XTI Aerospace received a Nasdaq deficiency notice on August 26, 2026 for failing to timely file its Q2 2026 Form 10-Q, due to an internal review of its former CEO who resigned on August 17, 2026. The company has 60 days (until October 26, 2026) to submit a compliance plan, and if accepted, Nasdaq may grant an exception until February 22, 2027. However, the company warns it may disclose substantial doubt about its ability to continue as a going concern, and there is no assurance it will regain compliance or maintain its listing.

  • · The company expects the Form 10-Q to disclose substantial doubt about its ability to continue as a going concern.
  • · The former CEO resigned on August 17, 2026, triggering the internal review.
  • · The company has not yet estimated when the internal review or the Form 10-Q filing will be completed.
  • · If Nasdaq does not accept the compliance plan, the company may appeal to a Nasdaq Hearings Panel.
  • · The Notice has no immediate effect on the listing of the company's common stock on the Nasdaq Capital Market.
Borealis Foods Inc. 8-K negative materiality 8/10

01-09-2026

Borealis Foods Inc. (BRLS) received a deficiency notice from Nasdaq on August 26, 2026, for failing to timely file its Q2 2026 Form 10-Q, violating Listing Rule 5250(c)(1). The company has until October 26, 2026, to submit a compliance plan, with a possible extension to February 16, 2027, if accepted. The delay is attributed to a review of accounting treatment for a Conversion Agreement requiring shareholder approval, but the notice has no immediate impact on trading.

  • · The company's securities (Common Shares and Warrants) continue to trade on the Nasdaq Capital Market without immediate effect.
  • · The compliance plan deadline is October 26, 2026; if accepted, Nasdaq may grant up to 180 calendar days from the Q2 2026 Form 10-Q due date, i.e., until February 16, 2027.
  • · The filing delay is specifically due to a review of the accounting treatment for a previously disclosed Conversion Agreement, which requires shareholder approval under Nasdaq rules.
U.S. GoldMining Inc. 8-K negative materiality 6/10

01-09-2026

U.S. GoldMining Inc. received a Nasdaq notice on August 27, 2026, stating it no longer complies with audit committee independence requirements (Listing Rule 5605) following the resignation of board member Aleksandra Bukacheva, who also chaired the Audit Committee. The company has a cure period until the earlier of its next annual shareholders' meeting or August 14, 2027 (or February 10, 2027 if the meeting is held before that date) to regain compliance. The Board is actively searching for an independent director to fill the vacancy, and there is no immediate effect on the company's Nasdaq listing.

  • · The resignation was effective August 14, 2026, and was not due to any disagreement with the company.
  • · Nasdaq Listing Rule 5605(c)(2) requires the Audit Committee to have at least three independent directors.
  • · The cure period extends to the earlier of the next annual shareholders' meeting or August 14, 2027, with an accelerated deadline of February 10, 2027 if the meeting occurs before that date.
  • · The company is an emerging growth company as defined under SEC rules.
authID Inc. 8-K negative materiality 9/10

01-09-2026

authID Inc. received a Nasdaq deficiency notice on August 27, 2026, for failing to maintain a minimum bid price of $1.00 per share for 30 consecutive business days. The company has a 180-day cure period until February 23, 2027, and may consider a reverse stock split. However, authID is also not in compliance with Nasdaq's stockholders' equity requirement, which could block access to a second compliance period and increase delisting risk.

  • · The deficiency period ran from July 16, 2026 through August 26, 2026.
  • · If the company does not regain compliance by February 23, 2027, it may be eligible for an additional 180-day compliance period, but only if it meets all other initial listing standards for the Nasdaq Capital Market, including the stockholders' equity requirement.
  • · The company is already not in compliance with the stockholders' equity requirement (Nasdaq Listing Rule 5550(b)(1)), as previously disclosed on August 21, 2026.
  • · If authID is not eligible for a second compliance period or appears unable to cure the deficiency, Nasdaq will initiate delisting proceedings, subject to appeal to a Nasdaq Hearings Panel.
CID Holdco, Inc. 8-K negative materiality 9/10

01-09-2026

CID HoldCo, Inc. (DAICW) received a third Nasdaq staff determination on August 27, 2026, for potential delisting due to failure to file its Form 10-Q for the period ended June 30, 2026. This adds to prior delisting bases for failing to meet the $50 million MVLS and $15 million MVPHS requirements. The company has requested a hearing and intends to seek an extended stay, but there is no assurance of continued listing.

  • · The company has seven days from August 27, 2026 (until September 3, 2026) to request an extended stay of suspension pending the Hearings Panel's decision.
  • · The hearing request regarding the delinquent filing stays suspension for 15 days from the date of request unless a further stay is granted.
  • · The company's common stock remains listed on Nasdaq pending the outcome of the hearing.
  • · The warrants (DAICW) are exercisable for one share of common stock at $287.50 per share, reflecting a reverse stock split effective May 29, 2026.
Barinthus Biotherapeutics plc. 8-K negative materiality 9/10

01-09-2026

Barinthus Biotherapeutics plc (BRNS) filed an 8-K on September 1, 2026, announcing that the High Court of Justice of England and Wales sanctioned the Scheme of Arrangement related to its merger with Clywedog Therapeutics, Inc. Trading of its American Depositary Shares (ADSs) on Nasdaq is expected to be halted prior to the opening of trading on September 9, 2026, with the Scheme expected to become effective on that date. The company's plans for delisting and deregistration of the ADSs remain unchanged.

  • · The Merger Agreement was dated September 29, 2025, and involved Barinthus Biotherapeutics plc, Beacon Topco, Inc., Cdog Merger Sub, Inc., and Clywedog Therapeutics, Inc.
  • · The Scheme of Arrangement and a capital reduction of the share premium account were sanctioned by the Court on September 1, 2026.
  • · The Scheme is expected to become effective on September 9, 2026.
  • · Trading of ADSs on Nasdaq is expected to be halted prior to the opening of trading on September 9, 2026.
  • · The company is an emerging growth company as defined under the Securities Act.
Heritage Distilling Holding Company, Inc. 8-K negative materiality 9/10

01-09-2026

IP Strategy Holdings, Inc. (IPST) received a Nasdaq notification on August 26, 2026, for failing to timely file its Quarterly Report on Form 10-Q for the period ended June 30, 2026, violating Nasdaq Listing Rule 5250(c)(1). The company has 60 days (until October 26, 2026) to submit a compliance plan, with a possible extension to February 22, 2027. The company intends to file the Form 10-Q and regain compliance in September 2026, but there is no guarantee of success, and failure could lead to delisting.

  • · The Nasdaq notification has no immediate effect on the listing of the company's common stock.
  • · If Nasdaq does not accept the compliance plan, the company may appeal to a Nasdaq Hearings Panel.
  • · The company issued a press release on August 28, 2026, regarding the notification.

Get daily alerts with 8 investment signals, 8 risk alerts, 6 opportunities and full AI analysis of all 8 filings

Start free trial Browse all digests

$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.

More from: US Corporate Distress Financial Stress SEC Filings

August 21, 2026

US Corporate Distress Financial Stress SEC Filings — August 21, 2026

August 20, 2026

US Corporate Distress Financial Stress SEC Filings — August 20, 2026

August 19, 2026

US Corporate Distress Financial Stress SEC Filings — August 19, 2026

August 18, 2026

US Corporate Distress Financial Stress SEC Filings — August 18, 2026

🇺🇸 More from United States

View all →

August 25, 2026

US Pre-Market SEC Filings Roundup — August 25, 2026

US Pre-Market SEC Filings Roundup

August 25, 2026

US Corporate Board Director Changes SEC Filings — August 25, 2026

US Corporate Board Director Changes SEC Filings

August 25, 2026

US Merger & Acquisition SEC Filings — August 25, 2026

US Merger & Acquisition SEC Filings

August 25, 2026

USA Insider Trading Pulse — August 25, 2026

USA Insider Trading Pulse
← All United States digests